Recognizing the role of intratumoral heterogeneity in limiting prior CAR T efficacy [59], a Phase 1 trial studied intrathecally delivered bivalent CAR T cells targeting both EGFR and IL13Rα2 in 6 patients with recurrent GBM [63]. The gene discussed is EGFR; the disease is glioblastoma.